全膝关节置换术和全髋关节置换术前阿片类药物处方及处方者有何变化?一项大型国家注册研究
该研究基于荷兰国家注册数据,分析2013至2018年因骨关节炎行全膝关节置换术(TKA)或全髋关节置换术(THA)患者术前一年阿片类药物处方情况。结果显示TKA和THA术前阿片处方比例分别从25%升至28%和从25%升至30%,主要因羟考酮处方增加,全科医生是主要处方者,但骨科医生处方比例亦上升。
要点
- TKA术前阿片处方比例从2013年25%升至2018年28%,THA从25%升至30%。
- TKA和THA术前每月阿片处方量分别增加3.96 MME和3.8 MME。
- 全科医生开具了82%至86%的术前阿片处方,骨科医生处方比例亦上升。
核心结论
- 2013至2018年荷兰术前阿片处方增加,主要因羟考酮处方增多,且术前一年内阿片处方亦增加。
- 全科医生是术前羟考酮主要处方者,但研究期间骨科医生处方亦增加。
- 作者认为骨科医生应在术前咨询中处理阿片使用及其相关负效应,更多跨学科合作似乎重要,需研究评估术前停用阿片是否降低不良结局风险。
研究设计与样本
- 大型数据库研究,链接荷兰药物统计基金会与荷兰关节置换注册中心2013至2018年数据。
- 纳入因骨关节炎行TKA或THA的18岁以上患者,通过年龄、性别、邮编和低分子肝素使用唯一链接。
- 最终TKA研究人群为40,989例(初始TKA的28%),THA研究人群为42,689例(初始THA的28%)。
- TKA和THA术前平均年龄均为68岁,约60%为女性。
- 采用线性回归调整年龄和性别分析阿片暴露随时间变化。
主要发现
- TKA术前有阿片处方比例从2013年25%(1079/4298)升至2018年28%(2097/7460),差异3%(95%CI 1.35%至4.65%;p<0.001)。
- THA术前有阿片处方比例从2013年25%(1111/4451)升至2018年30%(2323/7625),差异5%(95%CI 3.8%至7.2%;p<0.001)。
- TKA术前阿片处方量每月增加3.96 MME(95%CI 1.8至6.1 MME;p<0.001),THA每月增加3.8 MME(95%CI 1.5至6.0;p=0.001)。
- TKA和THA术前羟考酮处方量每月分别增加3.8 MME(95%CI 2.5至5.1;p<0.001)和3.6 MME(95%CI 2.6至4.7;p<0.001)。
- TKA术前曲马多处方量每月减少0.6 MME(95%CI -1.0至-0.2;p=0.006),THA无此变化。
关键数值与推荐
- TKA术前10至12个月与最后3个月相比,阿片处方量平均增加48 MME(95%CI 39.3至56.7 MME;p<0.001);THA增加121 MME(95%CI 110至131 MME;p<0.001)。
- TKA术前10至12个月和7至9个月,2013至2018年间处方量平均差异分别为61 MME(95%CI 19.2至103.3;p=0.004)和66 MME(95%CI 22.0至110.9;p=0.003)。
- THA术前所有四个季度2013至2018年间MME均增加,平均差异范围43.9至55.4 MME(p<0.05)。
- 全科医生开具的术前阿片处方平均比例范围为82%至86%(TKA 41,037/49,855;THA 49,137/57,289)。
- 骨科医生处方比例从THA的3%升至7%(差异4%[95%CI 3.6至4.9]),TKA从4%升至10%(差异6%[95%CI 5%至7%];p<0.001)。
临床怎么用
- 作者认为骨科医生应在术前咨询中处理阿片使用及其相关负效应。
- 作者认为更多跨学科合作似乎重要,以限制术前阿片处方。
- 作者建议需研究评估术前停用阿片是否降低不良结局风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Opioid use before TKA or THA is linked to a higher risk of revision surgery and less functional improvement. In Western countries, the frequency of preoperative opioid use has varied, and robust information on temporal changes in opioid prescriptions over time (in the months before surgery as well as annual changes) and among prescribers is necessary to pinpoint opportunities to improve on low-value care patterns, and when they are recognized, to target physician populations for intervention strategies. QUESTIONS/PURPOSES: (1) What proportion of patients undergoing arthroplasties receive an opioid prescription in the year before TKA or THA, and what were the preoperative opioid prescription rates over time between 2013 and 2018? (2) Does the preoperative prescription rate vary between 12 and 10 months and between 3 and 1 months in the year before TKA or THA, and did it change between 2013 and 2018? (3) Which medical professionals were the main prescribers of preoperative opioids 1 year before TKA or THA? METHODS: This was a large-database study drawn from longitudinally maintained national registry sources in the Netherlands. The Dutch Foundation for Pharmaceutical Statistics was linked to the Dutch Arthroplasty Register from 2013 to 2018. TKAs and THAs performed because of osteoarthritis in patients older than 18 years, which were also uniquely linked by age, gender, patient postcode, and low-molecular weight heparin use, were eligible. Between 2013 and 2018, 146,052 TKAs were performed: 96% (139,998) of the TKAs were performed for osteoarthritis in patients older than 18 years; of them, 56% (78,282) were excluded because of our linkage criteria. Some of the linked arthroplasties could not be linked to a community pharmacy, which was necessary to follow patients over time, leaving 28% (40,989) of the initial TKAs as our study population. Between 2013 and 2018, 174,116 THAs were performed: 86% (150,574) were performed for osteoarthritis in patients older than 18 years, one arthroplasty was excluded because of an outlier opioid dose, and a further 57% (85,724 of 150,574) were excluded because of our linkage criteria. Some of the linked arthroplasties could not be linked to a community pharmacy, leaving 28% (42,689 of 150,574) of THAs, which were performed between 2013 and 2018. For both TKA and THA, the mean age before surgery was 68 years, and roughly 60% of the population were women. We calculated the proportion of patients undergoing arthroplasties who had at least one opioid prescription in the year before arthroplasty and compared data from 2013 to 2018. Opioid prescription rates are given as defined daily dosages and morphine milligram equivalents (MMEs) per arthroplasty. Opioid prescriptions were assessed by preoperative quarter and by operation year. Possible changes over time in opioid exposure were investigated using linear regression, adjusted for age and gender, in which the month of operation since January 2013 was used as the determinant and MME as the outcome. This was done for all opioids combined and per opioid type. Possible changes in opioid prescription rates in the year before arthroplasty were assessed by comparing the time period of 1 to 3 months before surgery with the other quarters. Additionally, preoperative prescriptions per operation year were assessed per prescriber category: general practitioners, orthopaedic surgeons, rheumatologists, and others. All analyses were stratified by TKA or THA. RESULTS: The proportion of patients undergoing arthroplasties who had an opioid prescription before TKA increased from 25% (1079 of 4298) in 2013 to 28% (2097 of 7460) in 2018 (difference 3% [95% CI 1.35% to 4.65%]; p < 0.001), and before THA increased from 25% (1111 to 4451) to 30% (2323 to 7625) (difference 5% [95% CI 3.8% to 7.2%]; p < 0.001). The mean preoperative opioid prescription rate increased over time between 2013 and 2018 for both TKA and THA. For TKA, an adjusted monthly increase of 3.96 MME was observed (95% CI 1.8 to 6.1 MME; p < 0.001). For THA, the monthly increase was 3.8 MME (95% CI 1.5 to 6.0; p = 0.001. For both TKA and THA, there was a monthly increase in the preoperative oxycodone rate (3.8 MME [95% CI 2.5 to 5.1]; p < 0.001 and 3.6 [95% CI 2.6 to 4.7]; p < 0.001, respectively). For TKA, but not for THA, there was a monthly decrease in tramadol prescriptions (-0.6 MME [95% CI -1.0 to -0.2]; p = 0.006). Regarding the opioids prescribed in the year before surgery, there was a mean increase of 48 MME (95% CI 39.3 to 56.7 MME; p < 0.001) for TKA between 10 and 12 months and the last 3 months before surgery. For THA, this increase was 121 MME (95% CI 110 to 131 MME; p < 0.001). Regarding possible differences between 2013 and 2018, we only found differences in the period 10 to 12 months before TKA (mean difference 61 MME [95% CI 19.2 to 103.3]; p = 0.004) and the period 7 to 9 months before TKA (mean difference 66 MME [95% CI 22.0 to 110.9]; p = 0.003). For THA, there was an increase in the MMEs prescribed between 2013 and 2018 for all four quarters, with mean differences ranging from 43.9 to 55.4 MME (p < 0.05). The average proportion of preoperative opioid prescriptions prescribed by general practitioners ranged between 82% and 86% (41,037 of 49,855 for TKA and 49,137 of 57,289 for THA), between 4% and 6% (2924 of 49,855 for TKA and 2461 of 57,289 for THA), by orthopaedic surgeons, 1% by rheumatologists (409 of 49,855 for TKA and 370 of 57,289 for THA), and between 9% and 11% by other physicians (5485 of 49,855 for TKA and 5321 of 57,289 for THA). Prescriptions by orthopaedic surgeons increased over time, from 3% to 7% for THA (difference 4% [95% CI 3.6 to 4.9]) and 4% to 10% for TKA (difference 6% [95% CI 5% to 7%]; p < 0.001). CONCLUSION: Between 2013 and 2018, preoperative opioid prescriptions increased in the Netherlands, mainly because of a shift to more oxycodone prescriptions. We also observed an increase in opioid prescriptions in the year before surgery. Although general practitioners were the main prescribers of preoperative oxycodone, prescriptions by orthopaedic surgeons also increased during the study period. Orthopaedic surgeons should address opioid use and its associated negative effects in preoperative consultations. More intradisciplinary collaboration seems important to limit the prescribing of preoperative opioids. Additionally, research is necessary to assess whether opioid cessation before surgery reduces the risk of adverse outcomes. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- van Brug HE, Nelissen RGHH, Rosendaal FR, et al. What Changes Have Occurred in Opioid Prescriptions and the Prescribers of Opioids Before TKA and THA? A Large National Registry Study. Clin Orthop Relat Res. 2023. PMID: 37099415. doi:10.1097/CORR.0000000000002653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。